Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00787982
Other study ID # VIS-BR-08-001
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received October 29, 2008
Last updated December 30, 2009
Start date September 2008
Est. completion date September 2010

Study information

Verified date December 2009
Source Visualase, Inc.
Contact Pamela Kribs, R.N., BSN
Phone 516-562-3058
Email pkribs@NSHS.edu
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

In this study, the Visualase Thermal Therapy System will be used on metastatic brain tumors that cannot be removed by surgery. Researchers want to find out if it is possible to use this new device in subjects with 1-3 metastatic brain tumor(s), each measuring 3 centimeters (cm) or smaller. The safety of the device will also be studied.


Description:

The Visualase Thermal Therapy System is FDA-cleared for thermal destruction of soft tissue in neurosurgery under MRI guidance. The device combines 3 previously FDA-cleared devices: the Visualase Cooled Laser Application System, which delivers the laser (energy) to the tumor tissue; the PhoTex , Diode Laser Series, which is the laser itself; and the Visualase ENVISION Workstation, which is the computer system that helps the surgeon plan and monitor your treatment.

The Visualase Thermal Therapy System will be used in this study to give subjects a type of therapy called Laser Interstitial Thermal Therapy (LITT). LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor. During the heating process, MRTI can be used to watch the temperatures around the applicator to make sure that the tumor receives enough treatment and that the normal tissues around the tumor do not get too hot.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 2010
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patient or family able and willing to give informed consent.

- Subjects with metastatic cancer to the brain who have failed at least one conventional therapy (surgery, stereotactic radiosurgery, and/or whole brain radiotherapy).

- Three or fewer previously treated or untreated lesion(s) in the brain.

- Tumor size = 3.0 cm in largest diameter.

- MR imaging is not contraindicated for the patient.

- Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as determined by the treating surgeon.

- Able and willing to attend all study visits.

- Karnofsky Performance Scale score >70 for patients over the age of 15.

- Lansky Play Scale >70 for patients 15 years of age or younger.

Exclusion Criteria:

- Patients or family unwilling or unable to give written consent.

- Patients who cannot physically fit in, or are too heavy for, the MRI scanner.

- Patients with contra-indications to MRI imaging, such as, but not limited to, pacemakers or defibrillators, non-compatible aneurysm clips, shrapnel, or other internal ferromagnetic objects.

- Known sensitivity to gadolinium-DTPA.

- Based on Treatment Planning Imaging (MR and/or CT):

- Brain edema and/or mass effect that causes midline shift or shift in wall of ventricle of more than 5 mm.

- Lesions localized in the brain stem.

- Lesions less than 5mm from primary branches of cerebral vessels, venous sinus, hypophysis or cranial nerves.

- Evidence of recent (<2 weeks) hemorrhage.

- Presence of more than 3 brain tumors at the time of enrollment.

- Symptoms and signs of increased intracranial pressure.

- Medical issues which prohibit the patient from undergoing surgery (as determined by the treating surgeon, anesthesiologist, IMPAC clinic, referring physician).

- Patients who are unable to receive corticosteroids.

- Positive pregnancy test for women of child-bearing age.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
MRI-Guided Laser Induced Thermal Therapy
LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor

Locations

Country Name City State
United States North Shore University Hospital Manhasset New York

Sponsors (1)

Lead Sponsor Collaborator
Visualase, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of technical success or failure to complete the initial procedure with no associated major complications. within 24 hours following the procedure No
Secondary Examination of the extent to which Visualase predictions based on MRTI data match lesion dimensions form post-therapy MRI assessments. Immediately following treatment (day 0) No
Secondary Estimates of durations, required facilities, required personnel, and costs for all aspects of the treatment procedure from day 0 to patient release No
Secondary Local control of treated lesions as defined by volume of lesions increasing by no more than 25% Day 30, 90, and 180 days post procedure No
Secondary Accrual of patient survival post Visualase therapy Sooner of 3 years or patient death No
Secondary Procedure-related morbidity and mortality 30, 90,180 days post procedure No
See also
  Status Clinical Trial Phase
Completed NCT02810899 - Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Phase 4
Withdrawn NCT00977795 - A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors Phase 1/Phase 2
Withdrawn NCT00555984 - Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors N/A
Completed NCT00038441 - Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas Phase 1/Phase 2
Recruiting NCT03619694 - Role of MR Spectroscopy in Brain Tumors
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Unknown status NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT01244737 - FLT-PET Imaging of Brain Tumors in Children Phase 2
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Terminated NCT00769093 - Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy Phase 1
Completed NCT00392119 - MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors Phase 1
Terminated NCT00038389 - Study of Vioxx and Radiation Therapy for Brainstem Glioma Phase 1
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Recruiting NCT05049148 - Platelets Activation in Brain Neoplasms N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT04712721 - Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Early Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Terminated NCT01954576 - NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A
Recruiting NCT05538130 - A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors Phase 1
Recruiting NCT04111588 - Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases

External Links